Pain Therapeutics completes a Phase I clinical study for PTI-125, a new experimental drug therapy to treat Alzheimer's Disease
Summary of Key Findings
- PTI-125 was safe and well-tolerated at all doses studied
- PTI-125 demonstrated favorable pharmacokinetics for further drug development
** charts before announcement **
No comments:
Post a Comment